So I personally love prami. I use it alot but so often I see people bashing it and touting caber. Now I have used Caber and I didnt like its effect nearly as much as I like prami for several reasons. Lets take a look at the compounds. See where they are similar, see where they are different, and see why in my opinion Prami is a clear choice when it comes to a dopamine agonist for our purposes.
So both compounds are dopamine agonists. The agonize activity at the dopamine receptor which causes increases in the levels of dopamine. Dopamine and Prolactin have an inverse relationship. In other words if one is high the other is low. So by increasing dopamine we can effectively reduce prolactin. Caber has a longer half life, prami a shorter one. So what the difference? Well they impact different dopamine receptors. There are 4 dopamine receptors and they are responsible for different functions. Caber acts primarily on d2 receptors which has an effect on reducing prolactin. Sounds great. Well Prami acts significantly on d 2,3,and 4 receptors. The functions of these receptors are as follows d2-treats hyperprolactemia. d3 is crucial for male sexual function. d4 is essential in the area of neuroprotectivity and anti oxidant properties. As you can see Prami offers the same benefits of caber but in addition several more. Particularly of note is the effect prami has on gh - increasing it substantially, the effect on sexual function, and the neuroprotective benefits.
Sides. This drives me crazy. All I hear is I hate prami it makes me sick . All you need to do is start low and slowly increase dosage. Problem solved. Now lets take a look at Caber and its side effects. Well first of it bears mentioning that 79% of people who take Caber have adverse side effects. Its also bears mentioning that a primary side of caber is severely impaired liver function and choleostasis. Another is it causes Vavular Heart Disease! Not with Prami! While Prami has sides they are minor compared to the above in frequency and severity.
Somehow along the way things get twisted and info misconstrued. The fact is Prami has less dangerous and less frequent sides, impacts more beneficial areas than caber, has a shorter half life so can be taken "as needed" doesn't have to steadily be taken like caber.
See Sometimes i use something and it works really well for me but i hear so much contradictory info that I have to look into it. This was exactly the case here. All in all man, in my opinion, Prami is the clear cut choice hands down - for me anyway. If you haven't tried it rather than parrot misinformation give it a go..its a pretty damn impressive fun compound. Sexual benefits are insanely amazing, sense of well being , deep sleep , reduces prolactin quickly, easily and readily available.
Next 19 nor cycle have prami an hand and give it a go...if its your first time or if its been a while. Do so with an open mind and I think you will be very pleased.
*a b c d Kvernmo T, H?rtter S, Burger E (August 2006). "A review of the receptor-binding and pharmacokinetic properties of dopamine agonists". Clinical Therapeutics 28 (8): 1065?78. doi:10.1016/j.clinthera.2006.08.004. PMID 16982285.
* a b Newman-Tancredi A, Cussac D, Audinot V, et al. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics 303 (2): 805?14. doi:10.1124/jpet.102.039875. PMID 12388667.
* "MedlinePlus Drug Information: Pramipexole (Systemic)". United States National Library of Medicine. Archived from the original on 2006-09-26. Retrieved 2006-09-27
*Schade, Rene; Andersohn, Frank; Suissa, Samy; Haverkamp, Wilhelm; Garbe, Edeltraut (2007-01-04). "Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation". New England Journal of Medicine 356 (1): 29?38. doi:10.1056/NEJMoa062222. PMID 17202453
* Zanettini, Renzo; Antonini, Angelo; Gatto, Gemma; Gentile, Rosa; Tesei, Silvana; Pezzoli, Gianna (2007-01-04). "Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease". New England Journal of Medicine 356 (1): 39?46. doi:10.1056/NEJMoa054830. PMID 17202454